Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Non-Current Debt (2018 - 2025)

BridgeBio Pharma's Non-Current Debt history spans 8 years, with the latest figure at $547.0 million for Q4 2025.

  • On a quarterly basis, Non-Current Debt fell 25.97% to $547.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $547.0 million, a 25.97% decrease, with the full-year FY2025 number at $547.0 million, down 25.97% from a year prior.
  • Non-Current Debt hit $547.0 million in Q4 2025 for BridgeBio Pharma, down from $564.1 million in the prior quarter.
  • Over the last five years, Non-Current Debt for BBIO hit a ceiling of $738.9 million in Q4 2024 and a floor of $90.8 million in Q1 2021.
  • Historically, Non-Current Debt has averaged $408.6 million across 5 years, with a median of $435.1 million in 2024.
  • Biggest five-year swings in Non-Current Debt: skyrocketed 378.3% in 2022 and later dropped 25.97% in 2025.
  • Tracing BBIO's Non-Current Debt over 5 years: stood at $430.8 million in 2021, then increased by 0.06% to $431.0 million in 2022, then increased by 3.59% to $446.4 million in 2023, then surged by 65.5% to $738.9 million in 2024, then dropped by 25.97% to $547.0 million in 2025.
  • Business Quant data shows Non-Current Debt for BBIO at $547.0 million in Q4 2025, $564.1 million in Q3 2025, and $738.9 million in Q4 2024.